IDH2 and central nervous system cancer: Although previous metabolomics/lipidomics studies have sought to discover biomarkers in brain cancers, particularly gliomas, these studies primarily focused on phenotyping particular mutants (e.g., IDH vs. wild-type) and did not cross-verify potential biomarkers against these phenotypes (e.g., 1p19q codeletion or malignancy).